BioSpace News Archive

Aytu BioScience, Inc. announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 1,666,667 shares of common stock of the Company, at a price to the public of $6.00 per share, less underwriting discounts and commissions.

Applied BioCode announced today that it has received Emergency Use Authorization (EUA) from the US FDA for the use of its BioCode® SARS CoV-2 molecular diagnostic assay with pooled patient samples*. Applied BioCode’s EUA permits the pooled testing of up to five individual specimens from patients suspected of having COVID-19. The BioCode® SARS CoV-2 Assay is run on the automated BioCode® MDx-3000 Molecular System

- Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced that the National Medical Products Administration (NMPA) has accepte

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announces that the first patient has been successfully enrolled a

Vivos Therapeutics, Inc., a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, announced the pricing of its initial public offering of 3,500,000 shares of its common stock at a public offering price of $6.00 per share.

BARDA-sponsored study shows second-generation hAd5 vaccine candidate in both subcutaneous and room temperature oral formulations inhibits SARS-CoV-2 virus replication to undetectable levels and clears infection within days in 100% of vaccinated non-human primates

Protagonist Therapeutics, Inc., a clinical stage biopharmaceutical company, announced the pricing of its previously announced underwritten public offering of 4,761,904 shares of its common stock at a price to the public of $21.00 per share.

Aural Analytics, Inc., the industry leader in speech neuroscience and speech analytics technologies, announced today the initiation of a multi-product pivotal study to demonstrate the safety and efficacy of its speech-based tools for measuring pulmonary function and speech motor function in amyotrophic lateral sclerosis (ALS).

The WBC Congress, which brings together the international community of biomaterials researchers, is the opportunity for the company and the research laboratory to jointly present the roadmap and the first results of the shared laboratory, whose activities started in January 2020.

Circuit Clinical joins a historic alliance of fifty life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research.